山卓霉素
| 中文名称 | 山卓霉素 |
|---|---|
| 中文同义词 | 山卓霉素 |
| 英文名称 | sandramycin |
| 英文同义词 | sandramycin;3-hydroxy-N-[23-[(3-hydroxyquinoline-2-carbonyl)amino]-8,11,28,31-tetramethyl-2,6,9,12,15,22,26,29,32,35-decaoxo-7,27-di(propan-2-yl)-5,25-dioxa-1,8,11,14,21,28,31,34-octazatricyclo[34.4.0.0^{16,21}]tetracontan-3-yl]quinoline-2-carboxamide;L-Valine, N-[(3-hydroxy-2-quinolinyl)carbonyl]-D-seryl-(2S)-2-piperidinecarbonylglycyl-N-methylglycyl-N-methyl-, bimol. (5→1'3),(5'→13)-dilactone |
| CAS号 | 100940-65-6 |
| 分子式 | C60H76N12O16 |
| 分子量 | 1221.32 |
| EINECS号 | |
| 相关类别 | 微生物代谢物;Antibiotic |
| Mol文件 | 100940-65-6.mol |
| 结构式 |  |
山卓霉素 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
|
Traditional Cytotoxic Agents
|
Sandramycin has antimicrobial activity wtih MIC values of 0.024 μg/mL, 0.012 μg/mL, 0.012 μg/mL, 0.098 μg/mL, 0.024 μg/mL, 12.5 μg/mL and 12.5 μg/mL for
Bacillus subtilis
(Rec
+
) A22508-2,
B. subtilis
(Rec
-
) A22509-2-2,
Staphylocccus aureus
209P-A9497,
S. aureus
(echinomycin-resistant) A9628,
Streptococcus faecalis
A96 1 1,
Escherichia coli
A151 19 and
E. coli
(actinomycin-sensitive) A21780 (AS-19), respectively.
Sandramycin inhibits cancer cells growth of L1210, B16, HCT118, RPMI8226, A431, RKO, SU-DHL6 and SU-DHL10 cells with IC
50
values of 0.02 nM, 0.07 nM, 0.8 nM, 3.8 nM, 3.1 nM, 1.3 nM, 5.9 nM and 3.3 nM, respectively.
Sandramycin (0.0125-1.6 mg/kg; intraperitoneal injection; daily; for 5 days; CDF1 female mice) treatment shows moderately active in vivo against leukemia P388 in mice.
| Animal Model: | CDF1 female mice injected with leukemia P388 cells |
| Dosage: | 0.0125 mg/kg, 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 5 days |
| Result: | Was moderately active in vivo against leukemia P388 in mice. |
安全信息
| 海关编码 | 29419000 |
|---|
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-19829 | 山卓霉素 Sandramycin | 100940-65-6 | 1mg | 7690元 |